Novel Hybrid Peptide Cecropin A (1-8)-LL37 (17-30) with Potential Antibacterial Activity

Int J Mol Sci. 2016 Jun 29;17(7):983. doi: 10.3390/ijms17070983.

Abstract

Hybridizing different antimicrobial peptides (AMPs) is a particularly successful approach to obtain novel AMPs with increased antimicrobial activity but minimized cytotoxicity. The hybrid peptide cecropin A (1-8)-LL37 (17-30) (C-L) combining the hydrophobic N-terminal fragment of cecropin A (C) with the core antimicrobial fragment of LL37 (L) was designed and synthesized. C-L showed higher antibacterial activity against all indicator strains than C and L, and no hemolytic activity to sheep erythrocytes was observed. C-L kills bacterial cells and causes disruption of surface structure, as determined by scanning electron microscopy. Synergistic effects were observed in the combination of C-L with several antibiotics (chloramphenicol, thiamphenicol, or neomycin sulfate) against Escherichia coli and Staphylococcus aureus.

Keywords: antibacterial activity; cecropin A (1–8)-LL37 (17–30); hemolytic activity; hybrid peptide; synergistic interaction.

MeSH terms

  • Animals
  • Anti-Bacterial Agents / adverse effects
  • Anti-Bacterial Agents / pharmacology*
  • Antimicrobial Cationic Peptides / adverse effects
  • Antimicrobial Cationic Peptides / pharmacology*
  • Chloramphenicol / adverse effects
  • Chloramphenicol / pharmacology
  • Erythrocytes / drug effects
  • Escherichia coli / drug effects
  • Hemolysis / drug effects
  • Microscopy, Electron, Scanning
  • Neomycin / adverse effects
  • Neomycin / pharmacology
  • Sheep
  • Staphylococcus aureus / drug effects
  • Thiamphenicol / adverse effects
  • Thiamphenicol / pharmacology

Substances

  • Anti-Bacterial Agents
  • Antimicrobial Cationic Peptides
  • Chloramphenicol
  • cecropin A
  • Thiamphenicol
  • Neomycin